Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection
Summary
The prevalence of H. pylori antibiotic resistance has reached an alarming level worldwide. Antibiotic stewardship programs should be urgently developed and implemented. However, H. pylori antimicrobial susceptibility testing (AST) is rarely offered, making local resistance patterns not easily available. Guideline-recommended empiric therapies (GR-ET) may no longer reliably achieve high cure rate in the era of increasing antibiotic resistance. susceptibility-guided tailored therapy (SG-TT) may be a good choice to solve this problem. The aims of this study are: 1. to compare the efficacy of SG-TT with GR-ET as rescue regimens for H. pylori eradication; 2. to compare the patient adherence and adverse effects of these treatment regimens; 3. to investigate factors that may influence H. pylori eradication by these treatment regimens.
Timeline
- Start
- 2022-04-11
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amoxicillin | Other / unclassified | 500 mg | — |
| Subject | Amoxicillin | Other / unclassified | 750 mg | — |
| Subject | Amoxicillin | Other / unclassified | 1000 mg | — |
| Comparator | Bismuth Potassium Citrate | Unknown | 120 mg | — |
| Subject | Clarithromycin | Small molecule | 500 mg | — |
| Subject | Levofloxacin | Small molecule | 500 mg | — |
| Subject | Metronidazole | Small molecule | 250 mg | — |
| Subject | Metronidazole | Small molecule | 500 mg | — |
| Subject | Rabeprazole | Small molecule | 20 mg | — |
| Comparator | Tetracycline | Unknown | 500 mg | — |